13-Methyltetradecanoic acid
Based on 1 Customer Validation
13-Methyltetradecanoic acid (13-MTD), a saturated branched-chain fatty acid with potent anticancer effects. 13-Methyltetradecanoic acid induces apoptosis in many types of human cancer cells.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 2485-71-4
- Formula: C15H30O2
- Molecular Weight:242.40
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Apoptosis Compound Library
HY-L003
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Lipid Compound Library
HY-L043
-
Orally Active Compound Library
HY-L061
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Cell Death Library
HY-L162
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Fatty Acids Compound Library
HY-L182
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Mouse Metabolite Compound Library
HY-L217
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Chinese Baijiu Compound Library
HY-L241
-
Natural Product Diversity Scaffold Library
HY-L245
-
Tonifying Traditional Chinese Medicine Monomer Compound Library
HY-L246
-
Mass Spectrometry Natural Product Library
HY-L262
Biological Activity
13-Methyltetradecanoic acid (13-MTD; 0-140 μg/mL; 12-24 hours) inhibits cell viability and proliferation in human bladder cancer cells by inducing apoptosis[1].
13-Methyltetradecanoic acid (13-MTD; 70 μg/mL; 2-48 hours) treatments results in significant accumulation of cells with sub-G1 DNA content in a time-dependent manner, with the proportion of sub-G1 phase DNA content ranging from 9.25% to 85.3% over 2-48 hours[1].
13-Methyltetradecanoic acid (13-MTD; 70 μg/mL; 2-24 hours) down-regulates Bcl-2 and up-regulates Bax. This promotes mitochondrial dysfunction, leading to the release of cytochrome c from the mitochondria to the cytoplasm, as well as the proteolytic activation of caspases. 13-Methyltetradecanoic acid down-regulates AKT phosphorylation and activates phosphorylation of p38 and c-Jun N-terminal kinase (JNK)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Bladder cancer cell lines T24, 5637, and UM-UC-3
-
Concentration:0 μg/mL, 35 μg/mL, 70 μg/mL, 105 μg/mL, and 140 μg/mL
-
Incubation Time:12 hours, 24 hours
-
Result:Inhibition of cell viability in a dose- and time-dependent manner.
-
Cell Line:Bladder cancer cell lines T24, 5637, and UM-UC-3
-
Concentration:70 μg/mL
-
Incubation Time:2 hours, 8 hours, 24 hours, or 48 hours
-
Result:Resulted in significant accumulation of cells with sub-G1 DNA content in a time-dependent manner.
-
Cell Line:T24, 5637, and UM-UC-3 cells
-
Concentration:70 μg/mL
-
Incubation Time:2 hours, 8 hours, 24 hours
-
Result:Down-regulated Bcl-2 and up-regulated Bax, and down-regulated AKT phosphorylation and activated phosphorylation of p38 and c-Jun N-terminal kinase (JNK).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/C nude mice injected with Jurkat lymphoma cells[2]
-
Dosage:70 mg/kg/day
-
Administration:Oral gavage; daily; for 30 days
-
Result:Effectively inhibited the growth in vivo in a xenograft model.
Chemical Information
-
CAS No. 2485-71-4
-
Appearance Solid
-
Molecular Weight 242.40
-
Formula C15H30O2
-
Color White to off-white
-
SMILES
CC(C)CCCCCCCCCCCC(O)=O
-
Synonyms
13-MTD; 13-Methylmyristic acid
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
Ethanol : ≥ 100 mg/mL (412.54 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.31 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.31 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.31 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tianxin Lin, et al. 13-Methyltetradecanoic acid induces mitochondrial-mediated apoptosis in human bladder cancer cells. Urol Oncol. May-Jun 2012;30(3):339-45. [Content Brief]
[2]. Qingqing Cai, et al. 13-methyltetradecanoic acid exhibits anti-tumor activity on T-cell lymphomas in vitro and in vivo by down-regulating p-AKT and activating caspase-3. PLoS One. 2013 Jun 7;8(6):e65308. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 4.1254 mL | 20.6271 mL | 41.2541 mL | 103.1353 mL |
| 5 mM | 0.8251 mL | 4.1254 mL | 8.2508 mL | 20.6271 mL | |
| 10 mM | 0.4125 mL | 2.0627 mL | 4.1254 mL | 10.3135 mL | |
| 15 mM | 0.2750 mL | 1.3751 mL | 2.7503 mL | 6.8757 mL | |
| 20 mM | 0.2063 mL | 1.0314 mL | 2.0627 mL | 5.1568 mL | |
| 25 mM | 0.1650 mL | 0.8251 mL | 1.6502 mL | 4.1254 mL | |
| 30 mM | 0.1375 mL | 0.6876 mL | 1.3751 mL | 3.4378 mL | |
| 40 mM | 0.1031 mL | 0.5157 mL | 1.0314 mL | 2.5784 mL | |
| 50 mM | 0.0825 mL | 0.4125 mL | 0.8251 mL | 2.0627 mL | |
| 60 mM | 0.0688 mL | 0.3438 mL | 0.6876 mL | 1.7189 mL | |
| 80 mM | 0.0516 mL | 0.2578 mL | 0.5157 mL | 1.2892 mL | |
| 100 mM | 0.0413 mL | 0.2063 mL | 0.4125 mL | 1.0314 mL |
13-Methyltetradecanoic acid Related Classifications
HY-131503 Related Classifications
Powered by Bioz